VH3810109
Sponsors
ViiV Healthcare
Conditions
HIV Infections
Phase 1
A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants
CompletedNCT05291520
Start: 2022-02-23End: 2023-04-10Updated: 2024-09-19
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
Active, not recruitingNCT07053384
Start: 2025-07-10End: 2028-09-06Updated: 2026-03-24